Factors associated with high short-acting beta2-agonist use in urban children with asthma. Butz A.M., Ogborn J., Mudd S., Ballreich J., Tsoukleris M., Kub J., Bellin M., & Bollinger M.E. 2015.
Factors associated with high short-acting beta2-agonist use in urban children with asthma [link]Paper  abstract   bibtex   
Background One goal of guideline-based asthma therapy is minimal use of short-acting beta2 agonist (SABA) medications. Inner-city children with asthma are known to have high SABA use. Objective To examine factors associated with high SABA use in inner-city children with asthma. Methods One hundred inner-city children with persistent asthma were enrolled into a randomized controlled trial of an emergency department (ED) and home intervention. All children underwent serologic allergen specific IgE and salivary cotinine testing at the ED enrollment visit. Pharmacy records for the past 12 months were obtained. Number of SABA fills during the past 12 months was categorized into low- to moderate- vs high-use groups. SABA groups were compared by the number of symptom days and nights, allergen sensitization, and exposures. Regression models were used to predict high SABA use. Results Mean number of SABA fills over 12 months was 3.12. Unadjusted bivariate analysis showed that high SABA users were more than 5 times more likely to have an asthma hospitalization, almost 3 times more likely to have an asthma intensive care unit admission, and more than 3 times more likely to have prior specialty asthma care or positive cockroach sensitization than low to moderate SABA users. In the final regression model, for every additional inhaled corticosteroid fill, a child was 1.4 times more likely and a child with positive cockroach sensitization was almost 7 times more likely to have high SABA use when controlling for prior intensive care unit admission, receipt of specialty care, child age, and income. Conclusion Providers should closely monitor SABA and controller medication use, allergen sensitization, and exposures in children with persistent asthma. Trial registration ClinicalTrials.gov, identifier NCT01981564. Copyright © 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
@misc{butz_a.m._factors_2015,
	title = {Factors associated with high short-acting beta2-agonist use in urban children with asthma},
	url = {http://www.elsevier.com/wps/find/journaldescription.reviewers/722283/description#description},
	abstract = {Background One goal of guideline-based asthma therapy is minimal use of short-acting beta2 agonist (SABA) medications. Inner-city children with asthma are known to have high SABA use. Objective To examine factors associated with high SABA use in inner-city children with asthma. Methods One hundred inner-city children with persistent asthma were enrolled into a randomized controlled trial of an emergency department (ED) and home intervention. All children underwent serologic allergen specific IgE and salivary cotinine testing at the ED enrollment visit. Pharmacy records for the past 12 months were obtained. Number of SABA fills during the past 12 months was categorized into low- to moderate- vs high-use groups. SABA groups were compared by the number of symptom days and nights, allergen sensitization, and exposures. Regression models were used to predict high SABA use. Results Mean number of SABA fills over 12 months was 3.12. Unadjusted bivariate analysis showed that high SABA users were more than 5 times more likely to have an asthma hospitalization, almost 3 times more likely to have an asthma intensive care unit admission, and more than 3 times more likely to have prior specialty asthma care or positive cockroach sensitization than low to moderate SABA users. In the final regression model, for every additional inhaled corticosteroid fill, a child was 1.4 times more likely and a child with positive cockroach sensitization was almost 7 times more likely to have high SABA use when controlling for prior intensive care unit admission, receipt of specialty care, child age, and income. Conclusion Providers should closely monitor SABA and controller medication use, allergen sensitization, and exposures in children with persistent asthma. Trial registration ClinicalTrials.gov, identifier NCT01981564. Copyright © 2015 American College of Allergy, Asthma \& Immunology. Published by Elsevier Inc. All rights reserved.},
	journal = {Annals of Allergy, Asthma and Immunology},
	author = {{Butz A.M.} and {Ogborn J.} and {Mudd S.} and {Ballreich J.} and {Tsoukleris M.} and {Kub J.} and {Bellin M.} and {Bollinger M.E.}},
	year = {2015},
	keywords = {*agonist, *asthma, *asthma/di [Diagnosis], *asthma/dt [Drug Therapy], *beta 2 adrenergic receptor stimulating agent/ct [Clinical Trial], *beta 2 adrenergic receptor stimulating agent/dt [Drug Therapy], *child, *human, Child, age, allergen, allergen/ec [Endogenous Compound], article, asthma/dt [Drug Therapy], bivariate analysis, city, cockroach, controlled study, corticosteroid, corticosteroid/dt [Drug Therapy], corticosteroid/ih [Inhalational Drug Administration], cotinine, cotinine/ec [Endogenous Compound], drug therapy, emergency ward, environmental exposure, exposure, female, home care, hospital admission, hospitalization, human, immunoglobulin E, immunoglobulin E/ec [Endogenous Compound], income, intensive care unit, major clinical study, male, medical record, model, night, nonhuman, pharmacy, priority journal, randomized controlled trial, registration, sensitization, serology, short acting drug, symptomatology, therapy, urban area}
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021